Avidity Biosciences Joins Rare Disease Day 2025: A Commitment to Delivering New Treatments for Rare Neuromuscular Diseases
SAN DIEGO, Feb. 28, 2025 – Avidity Biosciences, Inc., a pioneering biopharmaceutical company, is proud to join the global community in observing Rare Disease Day 2025. This annual awareness campaign, which takes place on the last day of February, brings attention to the challenges faced by individuals living with rare diseases, their families, caregivers, and healthcare providers. Avidity, a leading developer of Antibody Oligonucleotide Conjugates (AOCs™), is committed to advancing a new class of RNA therapeutics that could bring hope to those suffering from rare neuromuscular diseases.
The Challenges of Rare Neuromuscular Diseases
Rare neuromuscular diseases affect a relatively small percentage of the population, making them under-researched and often overlooked in the medical community. The World Health Organization (WHO) estimates that approximately 350 million people worldwide live with a rare disease, and many of these conditions are neuromuscular in nature. These diseases can significantly impact daily living, causing weakness, pain, and mobility issues.
Avidity’s Role in Developing New Treatments
Avidity Biosciences is dedicated to addressing the urgent need for new treatments for rare neuromuscular diseases. The company’s unique approach, which involves conjugating antibodies to oligonucleotides, has the potential to revolutionize the way these conditions are treated. This innovative technology, known as Antibody Oligonucleotide Conjugates (AOCs™), can target specific cells and tissues, delivering therapeutic RNA directly to the site of disease.
Impact on Individuals and Families
For individuals and families living with rare neuromuscular diseases, the prospect of new treatments offers hope and the possibility of improved quality of life. Many of these conditions currently have no approved therapies, leaving patients and their families feeling helpless and frustrated. Avidity’s commitment to developing AOCs™ for these conditions could provide much-needed relief and support.
Global Impact
The impact of Avidity’s work extends beyond the individual and their family. By advancing the development of new treatments for rare neuromuscular diseases, the company is contributing to the global effort to improve the lives of millions of people affected by these conditions. Rare Disease Day is an opportunity to raise awareness about the challenges faced by those living with rare diseases and to show solidarity with the global community working to find solutions.
Conclusion
Avidity Biosciences’ participation in Rare Disease Day 2025 underscores its commitment to delivering new treatments for rare neuromuscular diseases using its innovative Antibody Oligonucleotide Conjugate (AOC) technology. This groundbreaking approach has the potential to transform the lives of those affected by these conditions, offering hope and improved quality of life. By continuing to invest in research and development, companies like Avidity are helping to build a brighter future for the millions of people living with rare diseases worldwide.
- Rare Disease Day highlights the challenges faced by individuals living with rare diseases, their families, caregivers, and healthcare providers.
- Avidity Biosciences is committed to developing Antibody Oligonucleotide Conjugates (AOCs™) for rare neuromuscular diseases.
- AOCs™ have the potential to deliver therapeutic RNA directly to the site of disease, offering hope for those with no approved treatments.
- Avidity’s work contributes to the global effort to improve the lives of millions of people affected by rare diseases.
